Rapid and fast acting anti-malarials are essential to treat severe malaria. Quinine has been
the only option for parenteral therapy until recently. While current evidence shows that …

Participants in both consultations Dr CJ Canfield, Pharmaceutical Systems Incorporated,
Gaithersburg, Maryland, United States of America.

Objective To explore the cost‐effectiveness of artesunate against quinine based principally
on the findings of a large multi‐centre trial carried out in Southeast Asia. Methods Trial data …

Background Artemisinin-based combination therapies (ACTs) are the mainstay for the
management of uncomplicated malaria cases. However, up-to-date data able to assist sub …

Background In the treatment of severe malaria, intravenous artesunate is more rapidly acting
than intravenous quinine in terms of parasite clearance, is safer, and is simpler to …

The second revised edition of a pocket-sized guide to the rapid diagnosis and management
of severe P. falciparum malaria. In view of the complexities of management the need for …

Background Severe malaria results in over a million deaths every year, most of them in
children aged less than five years and living in sub-Saharan Africa. Injectable artesunate …

Background New malaria treatment guidelines in Tanzania have led to the large-scale
deployment of artemether-lumefantrine (Coartem®), popularly known as ALu or dawa …

Background Prompt diagnosis and effective treatment are considered the cornerstones of
malaria control and artemisinin-based combination therapy (ACT) is currently the main anti …

Abstract Background The Tanzanian National Malaria Control Programme (NMCP) and its
partners have been implementing regular therapeutic efficacy studies (TES) to monitor the …